This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo

The AstraZeneca Competition Case: Patent Strategies Constituting Abuse of Dominance

Abstract

On 6 December 2012, the Court of Justice of the European Union affirmed that AstraZeneca abused its dominant position by engaging in certain intellectual property strategies aimed at protecting its product against generic competition. The judgement provides guidance on when life science companies abuse their dominant position through abuse of intellectual property and regulatory procedures. This article analyses the decision and discusses in particular how AstraZeneca’s patent strategies were caught by Article 102 of the Treaty on the Functioning of the European Union.

Read Paper

Author

Portrait image of Bart Goddyn
Bart Goddyn
Senior Legal Counsel, TiGenix , Belgium

Bart Goddyn is a senior legal counsel with several years of experience as an attorney in international law practices, as in-house counsel and as legal consultant to international companies. Bart is a Belgian-qualified attorney, with a Master of Law degree from the University of Leuven (KUL), an LL.M. in Intellectual Property law from the University of Brussels (KUB) and an LL.M. in Competition Law and Economics from the Brussels School of Competition (BSC). Bart focuses on transactional and advisory work and has particular legal expertise in intellectual property, ICT, media, antitrust, litigation management and compliance. His practice cuts across all fields of technology, including Pharma, Life Sciences, Health Care, Food and Nutrition, ICT, Media, Manufacturing and Industrial Services and Financial Institutions. Bart was Intellectual Property lawyer EMEA at Cargill and legal consultant for Johnson & Johnson. He is currently a legal consultant to TiGenix, a leading European cell therapy company, where he covers the broad range of legal matters relevant to the bio-tech industry. Bart is an official arbitrator at the Czech Arbitration Court in Prague and he lectures on Media and Intellectual Property law at the Hogeschool-Universiteit Brussel (HUB).

Company

TiGenix  logo

TiGenix

TiGenix NV (Euronext Brussels and Nasdaq: TIG?) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.

Related Papers

Payback Time: Trump and EU’s “Exorbitant” Fines vs US Tech Companies
The election of Donald Trump for a second term of the US Presidency is of considerable concern to the European Union (EU), NATO, and states worldwide in general owing to...Read more
Portrait image of Roy Girasa
Roy Girasa
Professor of Law, Pace University, USA
The Competition (Amendment) Act, 2023 and its Impact on Inter-Corporate Deliberations
The Parliament of India enacted the Competition (Amendment) Act, 2023 (“Amendment Act”), which was initially introduced as a Bill in August 2022, during the Monsoon Session. This legislation, which...Read more
Portrait image of Nupur Nadir
Nupur Nadir
Head - Legal, GEPL, GMR Group, India
Portrait image of Sreyasi Banerjee
Sreyasi Banerjee
Associate Manager - Legal Counsel, GMR Group, India
Keeping Competition Law Compliance Fresh in a VUCA World
Executives frequently use the military acronym VUCA – Volatility, Uncertainty, Complexity, Ambiguity – to describe the world in which they operate. In this article, we look at some ways to...Read more
Portrait image of Ian Rose
Ian Rose
VP Compliance, Volvo Trucks, Sweden
Portrait image of Julia Kelley
Julia Kelley
Vice President, Legal & Compliance, AB Volvo Penta, Sweden
AI and Inventorship
Artificial intelligence (AI) is a cutting-edge technology that has been generating substantial attention worldwide recently, including in the patent community. Balancing the rapid development in AI and adapting the patent...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India